The US FDA has approved centanafadine, marketed as Simtriyo, offering a new, potentially better-tolerated medication for ADHD patients, though questions remain about its comparative efficacy and place in therapy amidst existing treatments.
The US Food and Drug Administration has approved centanafadine, sold as Simtriyo, for attention-deficit hyperactivity disorder in adults and children aged 6 and over, giving Otsuka Pharmaceutical a new treatment in a crowded market where the biggest questions are not whether a drug beats placebo, but how it compares with established options and what kind of patients are most likely to benefit. Otsuka says the medicine is the first and only norepinephrine, dopamine and serotonin reuptake inhibitor approved for ADHD, and the author of the Psychology Today analysis argues that the label deserves a closer reading than much of the early coverage received.
The company’s case rests on four pivotal Phase 3 trials, while published adult data from 2022 reported statistically significant improvements in symptom scores at 200 mg and 400 mg doses, with effect sizes in the range of -0.24 to -0.40. That is a real benefit, but it is not a large one when set alongside the effect sizes typically seen with amphetamines and methylphenidate in broader comparative research. The drug’s chemistry also appears less balanced than the marketing suggests: the published binding data point to a medication that acts mainly on norepinephrine, with weaker activity at dopamine and serotonin transporters.
Evidence from the adolescent trial, published this year, suggests the drug can separate from placebo early, with symptom improvements seen as soon as Week 1. But the fine print matters. The available data indicate that the earliest gains were concentrated in inattention, while hyperactivity and impulsivity improved later and less robustly. In adults, the picture was mixed even across identically designed studies, with one trial separating from placebo within a week and another not doing so until later.
That leaves the central question patients and clinicians care about: how does it compare with what is already on the market? So far, there is no direct head-to-head trial against another ADHD drug. Otsuka has pointed to indirect comparisons and to a separate Phase 3b study in adults with ADHD and comorbid anxiety that reported positive top-line results, but the indirect analyses cannot establish true equivalence. One comparison found centanafadine inferior to lisdexamfetamine, while others were not statistically different from methylphenidate, atomoxetine or viloxazine.
The most defensible argument for Simtriyo may be tolerability rather than potency. Otsuka describes a well-characterised safety profile, and the available trial data suggest fewer insomnia events than long-acting methylphenidate, which could make the drug useful for patients whose main barrier to stimulant treatment is sleep disruption. Even so, the trade-off is familiar in ADHD medicine: gentler side effects often come with a more modest effect. As the Psychology Today analysis notes, centanafadine may have a place for patients with predominantly inattentive symptoms or for those who have not tolerated existing non-stimulants, but its approval is better understood as an incremental addition than as a breakthrough.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
